← Back to Search

Bone Morphogenetic Protein

A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

Phase 2 & 3
Waitlist Available
Research Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture when compared to standard of care alone.

Eligible Conditions
  • Broken Bones

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: DExperimental Treatment1 Intervention
Standard of Care: Surgical fixation intervention
Group II: BExperimental Treatment1 Intervention
2.0 mg/mL rhBMP-2/CPM + surgical fixation
Group III: AExperimental Treatment1 Intervention
1.0 mg/mL rhBMP-2/CPM + surgical fixation
Group IV: CActive Control1 Intervention
Buffer/CPM + surgical fixation Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dibotermin alfa
FDA approved

Find a Location

Who is running the clinical trial?

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
625 Previous Clinical Trials
248,072 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,555 Previous Clinical Trials
14,867,604 Total Patients Enrolled
~19 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top